Educational reference only. Not medical advice. Research compounds are not for human or veterinary use.

TRT and HRT after 40: benefits, risks and what's changed

After 40, hormones start to come up in a lot of conversations. Men hear about testosterone replacement therapy, or TRT. Women in perimenopause and menopause hear about hormone therapy, often called HRT or menopausal hormone therapy (MHT). Both treatments can help the right person, and both carry real risks. The advice on menopause hormone therapy has also changed a great deal in the last few years, including new FDA labels in 2026. Here is what the evidence says, what it does not say and why every decision belongs with a licensed clinician.

TRT for men over 40: the short version

We cover testosterone in depth in our full TRT post. Here are the essentials.

Who it is for

  • Diagnosis takes two things: symptoms or signs of low testosterone, plus blood tests that are consistently low. The Endocrine Society asks for at least two early-morning blood tests (7 to 10 AM) showing low testosterone. One low reading is not enough.
  • It is replacement, not enhancement: the benefits in trials were shown in men with a confirmed deficiency.

What it can do

In the Testosterone Trials, 790 men aged 65 and older with low testosterone were studied. Testosterone improved all aspects of sexual function and improved mood and depressive symptoms. It did not improve energy.

What to watch for

  • Thicker blood: testosterone can raise the red blood cell count. An elevated hematocrit is a reason not to start.
  • Fertility: outside testosterone lowers sperm production. The Endocrine Society recommends against it for men planning to have children in the near term.
  • Prostate: testosterone can increase prostate size, and the guideline calls for PSA monitoring during treatment.
  • Skin and sleep: acne can occur, and so can sleep apnea, though rarely. Untreated severe sleep apnea is a reason not to start.

Heart safety and labeling

TRAVERSE followed 5,246 men aged 45 to 80. Major heart events occurred in 7.0% of men on testosterone and 7.3% on placebo, which met the trial's test for safety. Atrial fibrillation (3.5% versus 2.4%), acute kidney injury and pulmonary embolism were more common with testosterone.

On February 28, 2025, the FDA removed the cardiovascular language from the boxed warning on all testosterone products, added the TRAVERSE results and added a blood pressure warning, because monitoring studies confirmed that all testosterone products raise blood pressure. In June 2026, the FDA asked manufacturers to make further changes, including removing the limitation on use for age-related low testosterone. Those were announced as requested changes. A clinician can tell you what your product's current label says.

Menopause and perimenopause

Menopause is the point when a full year has passed since your last period. In the United States the average age is 52. Perimenopause is the transition before that. It can last two to eight years, and most women spend about four years in it.

Common symptoms include:

  • Hot flashes and night sweats, also called vasomotor symptoms
  • Sleep problems
  • Mood swings or irritability
  • Vaginal dryness
  • Irregular periods that may be heavier or lighter

Some symptoms fade with time. Others do not. Vaginal and urinary symptoms often get worse without treatment.

The Women's Health Initiative: what happened in 2002

The Women's Health Initiative (WHI) ran two large hormone trials in postmenopausal women aged 50 to 79:

  • The combined arm: 16,608 women with a uterus took estrogen plus a progestin or placebo. It was stopped early in 2002, after an average of 5.2 years, because overall risks outweighed benefits.
  • The estrogen-alone arm: about 10,700 women who had had a hysterectomy took estrogen alone or placebo. It ended in 2004 because of more strokes.

In the combined arm, for every 10,000 women per year, there were about 7 more heart disease events, 8 more strokes, 8 more pulmonary embolisms and 8 more invasive breast cancers. There were also about 6 fewer colorectal cancers and 5 fewer hip fractures.

How the interpretation changed

After 2002, several guideline groups advised against using hormones to prevent chronic disease. Over time, researchers looked more closely at who was in the trials:

  • Age: the average participant was about 63, roughly a decade older than the average age of menopause. That is not the typical woman seeking help for new hot flashes.
  • Timing: in a 2013 follow-up of the WHI, younger women (50 to 59) had more favorable results with estrogen alone. The age analyses have statistical limits, so they are not proof.
  • The two arms differed: combined therapy increased breast cancer, while estrogen alone was linked to a lower rate of breast cancer over the long term, which surprised researchers.

The WHI authors were clear that hormone therapy should not be used to prevent chronic disease, though it is appropriate for symptom relief in some women.

The Menopause Society position (2022)

The Menopause Society (formerly The North American Menopause Society) published its current hormone therapy position statement in 2022. Key points:

  • For most healthy women with symptoms who are younger than 60 or within 10 years of menopause, the benefits of hormone therapy outweigh the risks.
  • Starting later carries more risk. Women who start after 60 or more than 10 years past menopause face higher absolute risks, which matches the WHI age data.
  • No automatic stop date. Therapy does not need to be routinely stopped at 60 or 65. Continuing can be considered after evaluation and counseling, with periodic reassessment.
  • Early menopause is different. Women with early menopause or primary ovarian insufficiency can generally use hormone therapy at least until the average age of menopause, unless there is a reason not to.

Benefits of menopause hormone therapy

  • Hot flashes and night sweats: hormone therapy works better than nonhormonal medicines. One 2026 review estimated about 75% symptom improvement, compared with roughly 20% to 60% for nonhormonal medicines.
  • Sleep: a 2017 meta-analysis found hormone therapy improved sleep quality in women who had hot flashes. It showed no benefit in women without them.
  • Bone and fracture: hormone therapy prevents bone loss and fracture. In the WHI combined arm there were about 5 fewer hip fractures per 10,000 women per year.
  • Vaginal and urinary symptoms: genitourinary syndrome of menopause (GSM) includes dryness, painful sex, burning, urgency and repeat urinary infections. Low-dose vaginal estrogen relieves these symptoms with minimal absorption into the body, and a progestogen is not needed with it. The Menopause Society says vaginal estrogen may be used at any age and for an extended time if needed.

Risks of menopause hormone therapy

  • Blood clots: oral estrogen raises the risk of venous blood clots. Transdermal estrogen, through the skin, has been linked to lower clot risk than oral estrogen, and lower doses may also lower it.
  • Stroke: both WHI arms showed more strokes with hormones.
  • Breast cancer: combined estrogen plus progestin increased breast cancer in the WHI. Short-term use does not appear to raise the risk much. Estrogen alone did not raise it in the WHI.
  • Endometrial cancer: estrogen without a progestogen thickens the lining of the uterus. A 2025 Cochrane review found that estrogen alone probably increases the risk of endometrial hyperplasia, a precursor to cancer, at all doses. That is why women with a uterus who take systemic estrogen also need a progestogen.

Your own risk depends on your age, health history and the type of therapy. This is exactly the conversation to have with a licensed clinician.

Who should not use hormone therapy

A 2026 review in American Family Physician lists these as reasons not to use it:

  • Prior breast cancer or other estrogen-sensitive cancer
  • A past blood clot or stroke
  • Coronary artery disease
  • Active liver disease
  • Poorly controlled blood pressure
  • Vaginal bleeding without a known cause

Migraine with aura, a strong family history of hormone-sensitive cancers and high heart or clotting risk call for extra caution.

The 2025-2026 FDA label changes

  • November 10, 2025: the FDA asked makers of all menopausal hormone therapy products to remove boxed warning language on heart disease, breast cancer and probable dementia. The boxed warning on endometrial cancer stays for systemic estrogen-alone products. Heart and breast cancer information remains in the label outside the box.
  • February 12, 2026: the FDA approved the new labels for the first six products, across vaginal estrogen, estrogen alone, combined therapy and progestogen products. At that point, 29 companies had submitted proposed changes.
  • October 30, 2026: three more products, all estradiol patches, got updated labels, for nine so far.

Not every expert agreed with every detail. One menopause researcher, quoted by Healio, was surprised that the combined-therapy label did not mention higher clot risk. A label change also does not change your personal risk, so the conversation with your clinician still matters.

Nonhormonal options

  • Fezolinetant (Veozah): FDA-approved in May 2023 for moderate to severe hot flashes from menopause. In December 2024 the FDA added a boxed warning for rare but serious liver injury, with liver blood tests before and during treatment.
  • Elinzanetant (Lynkuet): FDA-approved in October 2025 for moderate to severe hot flashes from menopause. It blocks two brain receptors (NK1 and NK3) involved in temperature control. Sleepiness is a possible side effect. In September 2026 the FDA granted priority review for hot flashes in women taking hormone-blocking therapy for breast cancer. That use is not approved yet.
  • Older options: some antidepressants (SSRIs and SNRIs), gabapentin and clonidine. They are evidence-based but less effective than hormone therapy.

Testosterone for women

The evidence for testosterone in women is narrow:

  • One supported use: a 2019 global consensus position statement found that the only evidence-based use is low sexual desire that causes distress (hypoactive sexual desire disorder, or HSDD) in postmenopausal women.
  • No proven benefit elsewhere: the same statement found no effect on general wellbeing, and not enough evidence for cognition or bone.
  • Unknown long-term safety: the long-term safety of testosterone in women has not been established.
  • No FDA-approved product for women: in the United States, any use in women is off-label. Possible side effects include acne, extra facial hair, scalp hair thinning and a deeper voice.

The bottom line

For men over 40, TRT helps when low testosterone is real and confirmed, mainly with sexual function and mood, and it requires ongoing monitoring of blood counts, the prostate and blood pressure. TRAVERSE eased fears about heart attacks but not every risk.

For women, the story has shifted the most. The 2002 WHI results were real, but they came mostly from older women. For healthy women under 60 or within 10 years of menopause who have bothersome symptoms, current guidance says the benefits usually outweigh the risks. The FDA's 2026 labels reflect that. Risks still depend on age, health history, the route and whether a progestogen is used. Nonhormonal options now include two newer medicines, and testosterone for women has evidence only for low desire.

Hormones are not one-size-fits-all. A licensed clinician who knows your history is the right person to weigh them with you.

Key references

This post is educational. It does not give dosing guidance and is not medical advice. Decisions about hormone therapy belong with a licensed clinician.

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

All blog posts